Concert Pharmaceuticals Stock Shares Owned By Institutions
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
Concert Pharmaceuticals fundamentals help investors to digest information that contributes to Concert Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Concert Stock. The fundamental analysis module provides a way to measure Concert Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Concert Pharmaceuticals stock.
Concert |
Concert Pharmaceuticals Company Shares Owned By Institutions Analysis
Concert Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Concert Pharmaceuticals Shares Owned By Institutions | 77.05 % |
Most of Concert Pharmaceuticals' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Concert Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 77% of Concert Pharmaceuticals are shares owned by institutions. This is 72.61% higher than that of the Biotechnology sector and 62.22% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 96.51% lower than that of the firm.
Concert Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Concert Pharmaceuticals' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Concert Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Concert Pharmaceuticals by comparing valuation metrics of similar companies.Concert Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers.
Concert Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 86.63 M | |||
| Shares Outstanding | 48.02 M | |||
| Shares Owned By Insiders | 3.77 % | |||
| Shares Owned By Institutions | 77.05 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | 3.08 X | |||
| Price To Book | 1.67 X | |||
| Price To Sales | 7.05 X | |||
| Revenue | 32.58 K | |||
| Gross Profit | (54.98 M) | |||
| EBITDA | 1.4 M | |||
| Net Income | (80.05 K) | |||
| Cash And Equivalents | 154.57 M | |||
| Cash Per Share | 3.22 X | |||
| Total Debt | 14.51 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 10.03 X | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | (55.15 M) | |||
| Short Ratio | 0.26 X | |||
| Earnings Per Share | (3.17) X | |||
| Target Price | 11.67 | |||
| Number Of Employees | 64 | |||
| Beta | 0.49 | |||
| Market Capitalization | 401.95 M | |||
| Total Asset | 165.32 M | |||
| Retained Earnings | (210.05 M) | |||
| Working Capital | 137.48 M | |||
| Current Asset | 144.11 M | |||
| Current Liabilities | 6.63 M | |||
| Z Score | 14.8 | |||
| Net Asset | 165.32 M |
About Concert Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Concert Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Concert Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Concert Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |